Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell lymphoma extra-large (Bcl-xL), encoded by the BCL2L1 gene, is a key anti-apoptotic protein belonging to the Bcl-2 family. Located primarily on the outer mitochondrial membrane, Bcl-xL plays a critical role in promoting cell survival by binding and sequestering pro-apoptotic proteins such as Bax, Bak, and BH3-only proteins, thereby preventing mitochondrial outer membrane permeabilization and the subsequent release of cytochrome c. In many human cancers, Bcl-xL is overexpressed, allowing malignant cells to evade apoptosis and develop resistance to chemotherapy and radiation. Consequently, Bcl-xL has emerged as an attractive therapeutic target. However, the clinical utility of small-molecule Bcl-xL inhibitors, such as navitoclax, has been severely limited by dose-limiting, on-target thrombocytopenia, as platelets rely heavily on Bcl-xL for survival. To overcome this toxicity, researchers have developed novel strategies, including selective Bcl-xL proteolysis-targeting chimeras (PROTACs) like DT2216, which target Bcl-xL for degradation via E3 ligases that are poorly expressed in platelets.
Inhibition of Bcl-xL anti-apoptotic activity by mimicking BH3-only proteins (BH3 mimetics) to disrupt interactions with pro-apoptotic proteins like Bax and Bak, or targeted degradation of Bcl-xL using proteolysis-targeting chimeras (PROTACs).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell lymphoma extra-large (Bcl-xL).